Analysis of severe adverse events reported among patients receiving isoniazid-rifapentine treatment for latent Mycobacterium tuberculosis infection — United States, 2012–2016

Details

• Alternative Title:
  Clin Infect Dis
• Personal Author:
  Schmit, Kristine M ; Wortham, Jonathan M ; Ho, Christine S ; Powell, Krista M
• Description:
  We analyzed data from 2012 to 2016 for patients who were hospitalized or who died after ≥1 dose of isoniazid-rifapentine for treatment of latent Mycobacterium tuberculosis infection. No patients died; 15 were hospitalized. Nine patients experienced hypotension, and 5 had elevated serum aminotransferases, reinforcing the need for vigilant monitoring during treatment.
• Subjects:
  Adverse Antitubercular Agents Article Drug Administration Schedule Drug Therapy, Combination Humans Isoniazid Latent Latent Tuberculosis Mycobacterium Tuberculosis Rifampin Rifapentine Tuberculosis United States

  More +
• Source:
  Clin Infect Dis. 71(9):2502-2505
• Pubmed ID:
  32185390
• Pubmed Central ID:
  PMC8020883
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  71
• Issue:
  9
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:9bc2e757875f2a72f6168d62c341868b8991a7414e14d4a7e3938445f3badc18
• Download URL:
  https://stacks.cdc.gov/view/cdc/104824/cdc_104824_DS1.pdf
• File Type:
  [PDF - 57.19 KB ]